CPH 0.00% 0.9¢ creso pharma limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

  1. 751 Posts.
    lightbulb Created with Sketch. 92
    Interesting quarterly. I'm not even going to pretend to understand the meta verse, but I'm sure it could be useful for marketing. Whether it's worth it, I couldn't even begin to speculate.

    The directors and EverBlu only stripped out $700k. Is this going in the right direction? Time will tell.

    Another capital raise is coming, and will likely need to be in the next quarter to avoid getting too tight. Will EverBlu be the lead on that, and how much will that cost? How will the legal issues impact the ability to raise needed cash? Or will someone step in and "help" by lightening the load - ie take some assets off Creso's hands?

    The increased revenue is promising (even pleasing I'd suggest), however the corporate/admin and marketing costs are way too high and just not close to sustainable. Revenue needs to be ten times current levels to think about this kind of spend.

    Anyway, all interesting and I'm sure will give people some things to talk and think about.

    DYOR and make your own calls...
 
watchlist Created with Sketch. Add CPH (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.